L3VLUP
ProSign in

VTRS · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

VTRSVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • VTRS
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterVTRSVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 202014 holders, $2.4bn30 holders, $18.4bn
Q1 202116 holders, $1.5bn31 holders, $15.4bn
Q2 20219 holders, $1.3bn30 holders, $12.7bn
Q3 202111 holders, $1.0bn35 holders, $10.1bn
Q4 202111 holders, $1.1bn28 holders, $12.4bn
Q1 20229 holders, $832m23 holders, $16.1bn
Q2 202213 holders, $1.0bn25 holders, $18.1bn
Q3 202212 holders, $714m22 holders, $18.4bn
Q4 202213 holders, $1.3bn28 holders, $18.4bn
Q1 202311 holders, $984m26 holders, $21.4bn
Q2 202313 holders, $1.1bn27 holders, $24.7bn
Q3 202313 holders, $1.1bn33 holders, $24.3bn
Q4 202310 holders, $1.1bn32 holders, $28.6bn
Q1 20248 holders, $1.3bn31 holders, $29.8bn
Q2 202412 holders, $1.1bn29 holders, $33.4bn
Q3 202413 holders, $1.2bn27 holders, $33.5bn
Q4 20249 holders, $1.4bn26 holders, $28.5bn
Q1 20259 holders, $819m21 holders, $35.4bn
Q2 202513 holders, $914m21 holders, $32.3bn
Q3 20259 holders, $1.1bn22 holders, $25.9bn
Q4 202510 holders, $1.3bn26 holders, $31.8bn
Q1 202613 holders, $1.4bn25 holders, $31.8bn
Q2 202612 holders, $3.1bn26 holders, $34.6bn
VTRS

Viatris Inc

Holders
10
Reported value
$1.1bn
Buyers
3
Sellers
8

Breadth -5 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only VTRS (3)

Arrowstreet Capital LP, GAMCO Investors Inc, Glenview Capital Management LLC

Only VRTX (25)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Tudor Investment Corp, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →